Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Herpes Zoster: full-pipeline trial registry
1 of 17 indexed Herpes Zoster trials are currently recruiting.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 1 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Herpes Zoster: 17 US clinical trials tracked, 1 recruiting.
Herpes Zoster is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 8 of these trials.
Enrollment posture brief
Registry condition herpes-zoster
OPEN 1 | RECR 6% | LATE 6 | EARLY 9 | RANK #1004 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Acquired Immunodeficiency Syndrome (6% recruiting · 18 trials)
Herpes Zoster lists 1 open slots (6% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Herpes Zoster on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Herpes Zoster is recruiting below its size-band peers.
1 of 17 indexed trials (5.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Herpes Zoster research.
GlaxoSmithKline accounts for 8 of 17 trials (47.1%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Herpes Zoster enrolment sits around 410 participants.
Median target enrolment is 410 among the 17 trials that report a genuine target (sentinel values excluded). 2 of those (11.8%) plan for fewer than 100 participants.
-
Herpes Zoster research is mostly interventional.
15 interventional and 2 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05580458
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
GlaxoSmithKline
NCT05371080
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
GlaxoSmithKline
NCT05811754
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
Curevo
NCT05304351
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ModernaTX
NCT05701800
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
Kevin Winthrop
NCT03604406
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
Shenzhen Shenxin Biotechnology Co.
NCT06375512
Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older
GlaxoSmithKline
NCT01165229
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
GlaxoSmithKline
NCT02690207
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
GlaxoSmithKline
NCT03439657
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
GlaxoSmithKline
NCT02045836
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
GlaxoSmithKline
NCT00802464
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
University of Colorado, Denver
NCT02114333
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
GlaxoSmithKline
NCT00920218
Persistence of Protection by Shingrix
University of Colorado, Denver
NCT04169009
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Curevo
NCT03820414
Immune Response to Varicella-Zoster Vaccination and Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00921999
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Herpes Zoster records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Herpes Zoster trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Herpes Zoster page
17 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Herpes Zoster trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Herpes Zoster trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Herpes Zoster condition card totals 17 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.